The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 21, Issue 3, 2006, Pages 235-240

  El Menyar, Ayman Ahmed ^a   Altamimi, O M ^a   Gomaa, Mohamed M ^a   Fawzy, Zainab ^a   Rahman, M O Abdel ^a   Bener, Abdulbari ^a  

^a HAMAD GENERAL HOSPITAL   (Qatar)

Author keywords

Angiotensin converting enzyme; Myocardial infarction; Plasminogen activator inhibitor; Reperfusion; Thrombolysis

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; PLASMINOGEN ACTIVATOR INHIBITOR; RETEPLASE; STREPTOKINASE; TENECTEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY REPERFUSION; DRUG TREATMENT FAILURE; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; Q WAVE; QATAR; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; THROMBOSIS;

ADULT; CORONARY CIRCULATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEINS; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33646413195     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-5484-x     Document Type: Article

References (23)

1. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988;77(6):1213-1220.
2. Smitherman TC. Considerations affecting selection of thrombolytic agents. Mol Biol Med 1991;8:207-218.
3. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-322.
4. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992;44:293-325.
5. Fujii S, Abendschein DR, Sobel BE. Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis. J Am Coll Cardiol 1991;18:1547-1557.
6. Levi M, Biemond B, van Zonnenweld AJ, ten Cate JW, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992;85:305-312.
7. Gray RP, Yudkin YS, Patterson DL. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: A role for plasminogen activator inhibitor? Br Heart J 1993;70:530-536.
8. Huber K, Beckman R, Rauscha F, Probst P, Kaindl F, Binder BR. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator. Z Kardiol 1993;82:195-200.
9. Hamsten H, de Faire, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;II:3-9.
10. Margaglione M, Di Minno G, Grandone E, et al. Abnormally high circulating levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arterioscler Thromb 1994;14:1741-1745.
11. Landin K, Tenborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med Res 1990;227:273-278.
12. Sane DC, Stump DC, Topol EJ, et al. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction. Thromb Haemost 1991;65:275-279.
13. Almer LO, Ohlin H. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction. Thromb Res 1987;47:335-339.
14. van Loon P, Rijkan DC, Bronmer EJP, et al. The amount of plasminogen, tissue type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 1992;67:101-105.
15. Sinkovic A: Prognostic role of plasminogen-activator-inhibitor-1 levels in treatment with streptokinase of patients with acute myocardial infarction. Clin Cardiol 2000;23:486-489.
16. Barbash GI, Hod H, Roth A, et al. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989;64:1231-1235.
17. Ridker PM, Vaughan, DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993;341:1165-1168.
18. Erdos EG. Angiotensin I-converting enzyme and the changes in our concepts through the years. Hypertension 1990;16:363.
19. Tiret L, Rigat B, Visvikis S, et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE. Am J Hum Genet 1992;51:197-205.
20. Cambien F, Costerousse O, Tiret L, et al. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction Circulation 1994;90:669- 676.
21. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism at the angiotensin-converting enzyme gene is a potent risk factor for myocardial infarction. Nature 1992;359:641- 644.
22. Hackworthy RA, Vogel MB, Harris PH. Relationship between changes in ST segment elevation and patency of the infarct related coronary artery in acute myocardial infarction. Am Heart J 1986;112:279-284.
23. Gore JM, Roberts R, Ball S, Montero A, Goldberg RJ, Dalen JE. Peak creatine kinase as a measure of effectiveness of thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1987;59:1234-1238.